Search clinical trials for: Monoklonal antistoffterapi

Total 3654 results

Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
Lawrence Fong
Genentech, Inc.

Recruiting

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Prostate Cancer | Prostate Adenocarcinoma | Localized Prostate Cancer

United States
Emory University
The Leukemia and Lymphoma Society

Recruiting

Rifaximin in Patients With Monoclonal Gammopathy

Waldenstrom Macroglobulinemia | Light Chain Deposition Disease | IgA Monoclonal Gammopathy | IgG Monoclonal Gammopathy | IgM Monoclonal Gammopathy | Monoclonal Gammopathy | Smoldering Waldenstrom Macroglobulinemia | Gammopathy, Monoclonal | Gammopathy Igg

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8 | Pathologic... and other conditions

United States
Imperial College London
Novartis Pharmaceuticals

Recruiting

IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)

Alcoholic Hepatitis

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
University of Washington
Pfizer

Recruiting

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes

United States
Yonsei University
Samsung Medical Center; AstraZeneca; Seoul National University Hospital; Korean... and other collaborators

Recruiting

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Platinum-resistant Recurrent Ovarian Cancer

Korea, Republic of
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Rahul Aggarwal
AstraZeneca

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Endometrial Cancer | Stage III Renal Cell Cancer | Locally Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IV... and other conditions

United States
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Osteosarcoma

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Indiana University

Recruiting

The Indiana Myeloma Registry

Plasma Cell Dyscrasias

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Mycosis Fungoides | Sezary Syndrome | Lymphomatoid Papulosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 Positive

United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Precision Biologics, Inc

Recruiting

Study of NEO-201 in Solid Tumors Expansion Cohorts

Cervical Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uterine Cancer

United States
Institut Bergonié
Bayer; Merck KGaA, Darmstadt, Germany

Recruiting

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Soft-tissue Sarcoma | Urothelial Carcinoma | Thyroid Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Biliary Tract Cancer | HPV-Related Carcinoma | Solid Tumor, Adult | Mesotheliomas Pleural | GIST | Renal Carcinoma | Colorectal... and other conditions

France
Centre Leon Berard
Roche Pharma AG

Recruiting

Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune)

Sarcoma,Soft Tissue

France, United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Lung Adenocarcinoma | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Eben Rosenthal
National Cancer Institute (NCI)

Recruiting

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Pancreatic Adenocarcinoma

United States
Genor Biopharma Co., Ltd.

Recruiting

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

Lymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
AstraZeneca
Parexel; MedImmune LLC

Recruiting

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Asthma

United States, Puerto Rico
Noah Hahn, M.D.
AstraZeneca; Hoosier Cancer Research Network

Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Bladder Cancer | Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Lymphoma | Epstein-Barr Virus Infections | Lymphoproliferative Disorder | Disorders, Lymphoproliferative

United States
Chinese PLA General Hospital

Recruiting

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

China
Bausch Health Americas, Inc.

Recruiting

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Psoriasis

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States

Search clinical trials for: Monoklonal antistoffterapi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations